Principal Street Partners, LLC Incyte Corp Transaction History

Principal Street Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$63.34 - $74.11 $513,117 - $600,365	-8,101 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$68.67 - $84.02 $262,800 - $321,544	-3,827 Reduced 32.08%	8,101 $557,000
Q2 2021 Aug 10, 2021	SELL	$79.87 - $87.53 $1.11 Million - $1.21 Million	-13,862 Reduced 53.75%	11,928 $1 Million
Q1 2021 May 13, 2021	BUY	$76.02 - $100.5 $911,555 - $1.21 Million	11,991 Added 86.9%	25,790 $2.1 Million
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $47,555 - $57,545	589 Added 4.46%	13,799 $1.2 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $996,163 - $1.46 Million	-13,429 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$63.18 - $85.97 $69,750 - $94,910	1,104 Added 8.96%	13,429 $983,000
Q4 2019 Mar 04, 2020	SELL	$73.04 - $95.72 $196,696 - $257,773	-2,693 Reduced 17.93%	12,325 $1.08 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $453,522 - $538,846	6,228 Added 70.85%	15,018 $1.11 Million
Q2 2019 Aug 15, 2019	BUY	$73.52 - $88.7 $59,918 - $72,290	815 Added 10.22%	8,790 $747,000
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $506,891 - $703,155	7,975 New	7,975 $686,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Principal Street Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Principal Street Partners, LLC with notifications on news.